CND LIFE SCIENCES, INC.
Scottsdale, AZ · Founded 2017 · CIK 0001841099 · Medtech · Private
Skin biopsy diagnostic test detecting phosphorylated α-synuclein to diagnose and predict progression of synucleinopathies
cndlifesciences.com →- Grants
- $12M
- 8 awards
- Sector median: 1
- Raised
- $19M
- 7 Form D · Jun 2026
- 3 months since last filing
- Contracts
- $146K
- 2 awards · Defense, Veterans Affairs
- #492 of 4531 in medtech
- Patents
- 2
- 0 granted · 2 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓2020202120222023202420252026
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase II · PHS 2019-02 Omnibus Solicitation of the NIH, CDC, and FDA for SmallBusiness Innovation Research Grant Applications (Parent SBIR [R43/R44] ClinicalTrial Not Allowed | $2,412,314 | |
| Private capital raised | Form D · SEC | $825,000 | |
| Federal grant | Department of Health and Human Services · Phase II · PHS 2019-02 Omnibus Solicitation of the NIH, CDC, and FDA for SmallBusiness Innovation Research Grant Applications (Parent SBIR [R43/R44] ClinicalTrial Not Allowed | $1,198,087 | |
| Private capital raised | Form D · SEC | $4,200,000 | |
| Federal grant | Department of Health and Human Services · Phase II · A Diagnostic Test for Dementia with Lewy Bodies | $2,408,271 | |
| Federal grant | Department of Health and Human Services · Phase II · Cutaneous Phosphorylated Alpha-Synuclein for Detection of Prodromal Synucleinopathies | $2,045,138 | |
| Private capital raised | Form D · SEC | $2,545,000 | |
| Federal grant | Department of Health and Human Services · Phase II · A Diagnostic Test for Dementia with Lewy Bodies | $1,168,467 | |
| Private capital raised | Form D · SEC | $1,457,000 | |
| Federal grant | Department of Health and Human Services · Phase II · Cutaneous Phosphorylated Alpha-Synuclein for Detection of Prodromal Synucleinopathies | $952,525 | |
| Federal contract | Department of Defense · UC187 FY22 - Syn-one Testing | $5,636 | |
| Private capital raised | Form D · SEC | $2,007,000 | |
| Federal grant | Department of Health and Human Services · Phase II · Cutaneous Phosphorylated Alpha-Synuclein for Detection of Prodromal Synucleinopathies | $954,862 | |
| Private capital raised | Form D · SEC | $3,514,565 | |
| Federal contract | Department of Veterans Affairs · Synone Esoteric Testing Services | $140,168 | |
| Federal grant | Department of Health and Human Services · Phase II · Analysis of Cutaneous Phosphorylated alpha-Synuclein to Identify Patients at Risk of Progressing from Essential Tremor to Parkinson's Disease | $1,276,662 | |
| Private capital raised | Form D · SEC | $4,314,750 |
Federal grant · SBIR/STTRFederal contract · USAspendingForm D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 489 | Cytoimage Inc. | $150K | $225K |
| 490 | CANTON BIOTECHNOLOGIES, INC. | $149K | — |
| 491 | Awarables, Inc. | $149K | $500K |
| 492 | CND LIFE SCIENCES, INC. | $146K | $19M |
| 493 | Vicis, Inc. | $141K | $67M |
| 494 | SOMARK INNOVATIONS INC | $140K | $300K |
| 495 | SYNAPSE BIOMEDICAL INC | $136K | $433K |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Enrique CarrazanaDirector
- Roy FreemanDirector
- Christopher GibbonsDirector
- Peter HarrisDirector · Executive Officer
- Todd LevineDirector · Executive Officer
- Richard MorelloDirector · Executive Officer
- Jack SeaverDirector
Patents
- Systems And Methods For Identifying And Treating Neurodegenerative Diseaseapplication
- Systems And Methods For Identifying And Treating Neurodegenerative Diseaseapplication
Regulatory activity · Medtech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.